Celldex Ends Esophagitis Treatment, Explores Other GI Uses
Celldex stopped barzolvolimab for eosinophilic esophagitis after it failed to improve symptoms, despite depleting mucosal mast cells. The company will now explore other GI diseases driven by mast cells where the antibody might be effective.